Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VentriGel in Pediatric HLHS
NCT06461676Phase 1Not yet recruiting
- Sponsor
- Emory University
- Start
- Aug 2025
- Primary completion
- Sep 2028
- Modality
- Hydrogel Systems, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VentriGel in hypoplastic left heart syndrome (HLHS), sponsored by Emory University. Primary endpoints: Number of ventricular tachycardia events, Number of Cardiogenic shock events and 7 more. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
VentriGel
03
Conditions
hypoplastic left heart syndrome (HLHS)
Beyond the preview
Go deeper on NCT06461676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06461676.